Market Overview

Teva, Perrigo Reports US Launch of Generic Temozolomide

Share:
Related TEVA
Report Sees 'Cognitive Dissonance' In Mylan's Internal Price Target
Analyst: Mylan Shareholders Might Get Convinced By Vigodman Letter
Mylan Q1 Earnings Meet Expectations, 2015 Guidance Upheld - Analyst Blog (Zacks)
Related PRGO
Analyst: Mylan Shareholders Might Get Convinced By Vigodman Letter
Benzinga's M&A Chatter for Wednesday April 29, 2015
Mylan Q1 Earnings Meet Expectations, 2015 Guidance Upheld - Analyst Blog (Zacks)

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Perrigo Company (NYSE: PRGO) today announced the launch of the generic equivalent to Temodar® (temozolomide). Teva will manufacture, market and distribute the product in the U.S. and both companies will equally share in the cost and profitability of the product in the U.S. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.

This product is the generic equivalent to Temodar® (temozolomide), indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment and refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. Temodar® had annual sales of approximately $423 million in the United States, according to IMS data as of December 31, 2012. The launch of this product provides a quality alternative, making cancer therapy more cost effective for patients who suffer from this devastating cancer.

Posted-In: News FDA

 

Related Articles (PRGO + TEVA)

Around the Web, We're Loving...